论文部分内容阅读
目的观察单药多西他赛联合3D-CRT同步治疗局部晚期非小细胞肺癌的疗效、作用机制和耐受性。方法 60例均经病理证实为鳞癌的初治病人,临床分期ⅢA-ⅢB。随机分成两组:观察组:(3D-CRT同步多西他赛增敏+辅助化疗)共30例,与放疗同步,多西他赛静脉滴注(36mg/m2),每周1次,从放疗第1天开始,共6周,放疗结束后TP方案辅助化疗2周期;对照组:(3D-CRT+辅助化疗)共30例,放疗结束后TP方案辅助化疗4-6周期。结果近期疗效(CR+PR):观察组/对照组80%/66.7%。观察组/对照组1、2、3年局控率分别为90.0%/80.0%、80.0%∕53.0%7、0.0%∕40.0%;12、、3年生存率分别是90.0%∕80.0%、73.0%∕47.0%、60.0%∕33.3%。通过对单药多西他赛周疗联合3D-CRT治疗局部晚期非小细胞肺癌的疗效观察发现,近期疗效观察组优于对照组(P<0.05,有统计学意义);23、年局控率及生存率观察组均优于对照组,两组均有统计学意义(P<0.05)结论单药多西他赛周疗联合三维适形放疗同步治疗局部晚期非小细胞肺癌疗效较好,毒副反应可耐受,值得临床推广。
Objective To observe the efficacy, mechanism of action and tolerability of monotherapy docetaxel combined with 3D-CRT in the treatment of locally advanced non-small cell lung cancer. Methods Sixty cases were all newly diagnosed as squamous cell carcinoma by pathology. The clinical stage ⅢA-ⅢB. Randomly divided into two groups: observation group: (3D-CRT simultaneous docetaxel sensitization + adjuvant chemotherapy) a total of 30 cases, synchronized with radiotherapy, docetaxel intravenous infusion (36mg / m2) once a week from The first day of radiotherapy started for 6 weeks. After the end of radiotherapy, the TP regimen adjuvant chemotherapy for 2 cycles; the control group: (3D-CRT + adjuvant chemotherapy) for 30 cases. After the radiotherapy, the TP regimen adjuvant chemotherapy for 4-6 cycles. Results The short-term response (CR + PR): observation group / control group 80% / 66.7%. The 1, 2 and 3-year local control rates in observation group and control group were 90.0% / 80.0%, 80.0% / 53.0%, 0. 0% / 40.0% and 12.0% / 90.0% respectively. 73.0% / 47.0%, 60.0% / 33.3%. The efficacy of single-dose docetaxel weekly combined with 3D-CRT in the treatment of locally advanced non-small cell lung cancer found that the recent efficacy observation group was better than the control group (P <0.05, statistically significant); (P0.05) .Conclusion Monotherapy docetaxel combined with three-dimensional conformal radiotherapy in the treatment of locally advanced non-small cell lung cancer is better than the control group, Toxicity can be tolerated, it is worth clinical promotion.